Mesoblast Limited logo

Mesoblast LimitedNASDAQ: MESO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Australia

IPO:

20 January 2010

Next earnings report:

31 January 2025

Last dividends:

N/A

Next dividends:

N/A
$1.18 B
-13%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-13%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 21:00:01 GMT
$10.33-$0.17(-1.62%)

Dividend

No data over the past 3 years
$4.19 M$1.13 M

Analysts recommendations

Institutional Ownership

MESO Latest News

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
globenewswire.com30 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024.

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
seekingalpha.com30 September 2024 Sentiment: POSITIVE

Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate that Remestemcel-L significantly improves response rates and survival in pediatric patients. Additionally, Mesoblast's pipeline includes late-stage therapies for chronic low back pain and heart failure, both of which are showing promising results and are nearing regulatory approval.

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
globenewswire.com29 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approval by the United States Food and Drug Administration (FDA) of Mesoblast's lead product candidate Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast's option and will enable the Company to seamlessly implement its go-to-market commercial strategy. Mesoblast anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025.

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
globenewswire.com28 August 2024 Sentiment: POSITIVE

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: “During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products.

Mesoblast Financial Results and Corporate Update Webcast
globenewswire.com27 August 2024 Sentiment: POSITIVE

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2024.

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
globenewswire.com21 July 2024 Sentiment: POSITIVE

NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product rexlemestrocel-L in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease of less than five years duration has commenced enrollment at multiple sites across the United States.

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
globenewswire.com08 July 2024 Sentiment: POSITIVE

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil® (remestemcel-L) in the treatment of children with SR-aGVHD.

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
globenewswire.com01 July 2024 Sentiment: POSITIVE

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.

Mesoblast Corporate Presentation at Investor Conference
globenewswire.com02 June 2024 Sentiment: POSITIVE

NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Zacks Investment Research27 March 2024 Sentiment: POSITIVE

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.

What type of business is Mesoblast Limited?

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

What sector is Mesoblast Limited in?

Mesoblast Limited is in the Healthcare sector

What industry is Mesoblast Limited in?

Mesoblast Limited is in the Biotechnology industry

What country is Mesoblast Limited from?

Mesoblast Limited is headquartered in Australia

When did Mesoblast Limited go public?

Mesoblast Limited initial public offering (IPO) was on 20 January 2010

What is Mesoblast Limited website?

https://www.mesoblast.com

Is Mesoblast Limited in the S&P 500?

No, Mesoblast Limited is not included in the S&P 500 index

Is Mesoblast Limited in the NASDAQ 100?

No, Mesoblast Limited is not included in the NASDAQ 100 index

Is Mesoblast Limited in the Dow Jones?

No, Mesoblast Limited is not included in the Dow Jones index

When was Mesoblast Limited the previous earnings report?

No data

When does Mesoblast Limited earnings report?

The next expected earnings date for Mesoblast Limited is 31 January 2025